Last month, we hosted our annual Portfolio Day at Green Village in Nieuwegein, The Netherlands. During the event, our LPs received an update on our latest fund, Thuja Capital Healthcare Fund III.
The half-day program combined company presentations and keynote lectures with ample networking time to connect and meet with portfolio companies’ management, as well as fellow LPs. The portfolio companies presented this year were:
Fundamental Pharma: a neuroscience company spun-out of Heidelberg University, developing first-in-class small molecule inhibitors for treatment of a range of devastating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease. FundaMental Pharma is our newest portfolio addition, launching with a €10M seed financing round in November 2022.
Pan Cancer T: a spin-off company of Erasmus Medical Center Rotterdam, developing novel adoptive T cell therapeutics for the treatment of solid tumors that currently have a poor prognosis.
EsoBiotec: a Belgium-based biotech company, developing next generation in vivo cell therapy for cancer treatment, with the aim to offer previously unattainable treatment options to the largest possible number of patients.
InnoSign: a precision medicine company spun-out from Royal Philips, developing a unique diagnostics platform that can predict how patients will respond to targeted cancer drugs.
Astrivax: a KU Leuven spin-off company, developing a highly innovative vaccine platform for the development of effective vaccines to treat and prevent infectious diseases in areas of critical unmet needs.
This year we also organized two keynote lectures: Jerome Custers, Sr. Scientific Director Vaccine Research at Janssen Vaccines gave us insight into the intriguing development of the Janssen Covid vaccine and Prof. Deborah Nas, taught us about technology-based innovation and the promise of quantum computing.
We will continue to build our portfolio, and are already looking forward to next year’s Portfolio Day!